Quality Improvement in Cardiovascular Disease Care

Author(s):  
Edward S. Lee ◽  
Rajesh Vedanthan ◽  
Panniyammakal Jeemon ◽  
Jemima H. Kamano ◽  
Preeti Kudesia ◽  
...  
Author(s):  
Jordan M. Kautz ◽  
Christopher M. Wittich

Preventive medicine focuses on preventing disease and keeping patients healthy. There are 3 levels of prevention: 1.Primary prevention: preventing disease before it occurs (eg, immunization to prevent disease, use of condoms to prevent sexually transmitted diseases); 2.Secondary prevention: detecting preclinical disease to start early treatment for better outcomes (eg, cancer screening, treating hypertension to prevent cardiovascular disease); and 3. Tertiary prevention: improving outcomes (quality of life, disease progression) in known disease (eg, use of aspirin after myocardial infarction to decrease recurrence, rehabilitation after a stroke).


2019 ◽  
Vol 48 (3) ◽  
pp. 263-274 ◽  
Author(s):  
Lucy R. VanOtterloo ◽  
Christine H. Morton ◽  
Marla J. Seacrist ◽  
Elliott K. Main

2020 ◽  
Vol 27 (8) ◽  
pp. 2323-2339
Author(s):  
Sharan Srinivas ◽  
Kavin Anand ◽  
Anand Chockalingam

PurposeWhile cardiovascular disease (CVD) is the leading cause of death globally, over 80% of the cases could be prevented through early lifestyle changes. From the perspective of quality management in healthcare, this may offer an effective prevention window if modifiable CVD risk factors are identified and treated in adolescence. The purpose of this research is to examine the negative emotions in adolescents and determine if it independently increases CVD risk later in life.Design/methodology/approachLongitudinal data from 12,350 participants of the Add Health study, which conducted a multi-wave survey for 14 years from adolescence (Wave 1) through adulthood (Wave 4), were used to test the research hypothesis. Four items (perception of life, self-reported depression, perceived loneliness and fearfulness) reflective of adolescent negative emotion were identified from the Wave 1 questionnaire, and factor analysis was conducted to confirm the hypothesized structure. The outcome variable, 30-year adulthood CVD risk category (high or low risk), was estimated using biomarkers, biological data and other factors collected during the 14-year follow-up in Wave 4. A logistic regression analysis was employed to assess the impact of adolescent negative emotions on adulthood CVD risk after adjusting for common risk factors such as sociodemographic characteristics, socioeconomic status and medical conditions in adolescence.FindingsThe results indicated adolescent negative emotion to be significantly associated with CVD risk category (p-value < 0.0001), even after controlling for common risk factors. A unit increase in the level of adolescent negative emotion increased the chance of being in the high CVD risk group in adulthood by 8% (odds ratio = 1.08 ± 0.03).Practical implicationsHealthcare providers and organizations could capitalize on the research findings by screening for negative emotions early in life through individual and societal interventions. The findings also provide an opportunity for implementing quality improvement initiatives to deliver robust preventive care, which, in turn, could improve the overall population health, reduce healthcare costs and improve care quality.Originality/valueAlthough previous studies showed a strong link between adolescent physiological factors (e.g. obesity) and adulthood cardiovascular disease (CVD), the association between adolescent outlook/attitude (negative emotion) and CVD risk has not been examined.


2021 ◽  
Author(s):  
Charlotte Hespe ◽  
Katrina Giskes ◽  
Mark Harris ◽  
David Peiris

Abstract Background There are discrepancies between evidence-based guidelines for screening and management of cardiovascular disease (CVD) and implementation in Australian general practice. Quality-improvement (QI) initiatives aim to reduce these gaps. This study evaluated a QI intervention (QPulse) that focussed on CVD assessment and management. MethodsThis mixed-methods study explored the implementation of guidelines and adoption of QI processes in 34 general practices. CVD screening and management were measured pre- and post-intervention. Qualitative analyses examined participants’ Plan-Do-Study-Act (PDSA) goals and in-depth interviews with practice stakeholders focussed on barriers and enablers to implementation and were analysed thematically using Normalisation Process Theory (NPT). ResultsPre- and post-intervention data were available from 15 practices (n=19562 and n=20249, respectively) and in-depth interviews from seven practices. At baseline, 45.0% of patients had their BMI measured and 15.6% had their waist circumference recorded in the past 2 years and blood pressure, lipids and smoking status were measured in 72.5%, 61.5% and 65.3% of patients, respectively. Most high-risk patients (57.5%) were not prescribed risk-reducing medications. After the intervention there were no changes in the documentation and prevalence of risk factors, attainment of BP and lipid targets or prescription of CVD risk-reducing medications. However, there was variation in performance across practices with some showing isolated improvements, such as recording waist circumference (0.7-32.2% pre-intervention to 18.5%-69.8% post-intervention), BMI and smoking assessment. Challenges to implementation included: lack of time, need for technical support, a perceived lack of value for quality improvement work, difficulty disseminating knowledge across the practice team, tensions between the team and clinical staff and a part-time workforce. ConclusionThe implementation barriers associated with this QI program was considerable in Australian GP practices. Findings highlighted they were not able to effectively operationalise the intervention due to numerous factors, ranging from lack of internal capacity and leadership to competing demands and insufficient external support. Trial registrationAustralian New Zealand Clinical Trials Reference Number (ACTRN12615000108516), registered 06/02/2015. Trial protocol can be accessed at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12615000108516


Sign in / Sign up

Export Citation Format

Share Document